Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm on June 15th

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, is inviting shareholders and interested parties to attend a June 15 capital mark...
Read more

Oasmia convenes an extraordinary general meeting on 2 June, 2017

Uppsala, Sweden, May 10, 2017 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company convenes to an extraordinary general meeting. The notice will ...
Read more

Oasmia Pharmaceutical to spin-off veterinary assets

The Company has decided to move its veterinary assets to its US subsidiary and appointed a New York based investment bank to assist in evaluating financial and strategical alternatives for those.
Read more
To news archive